Oppenheimer Asset Management Inc. Acquires 4,671 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Oppenheimer Asset Management Inc. lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 14.2% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 37,576 shares of the medical research company's stock after purchasing an additional 4,671 shares during the quarter. Oppenheimer Asset Management Inc. owned about 0.08% of Charles River Laboratories International worth $5,656,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. D1 Capital Partners L.P. bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $172,752,000. Assenagon Asset Management S.A. increased its holdings in shares of Charles River Laboratories International by 1,721.1% during the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company's stock valued at $85,811,000 after acquiring an additional 538,792 shares in the last quarter. Norges Bank acquired a new position in shares of Charles River Laboratories International during the fourth quarter worth approximately $98,886,000. Wellington Management Group LLP lifted its holdings in shares of Charles River Laboratories International by 9.0% in the 4th quarter. Wellington Management Group LLP now owns 4,076,426 shares of the medical research company's stock worth $752,508,000 after purchasing an additional 335,658 shares in the last quarter. Finally, Nomura Holdings Inc. acquired a new stake in Charles River Laboratories International in the 4th quarter valued at $56,820,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $145.41, for a total value of $72,705.00. Following the completion of the sale, the executive vice president now directly owns 19,513 shares of the company's stock, valued at $2,837,385.33. This trade represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the stock. Robert W. Baird upped their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 target price on the stock in a report on Wednesday, May 14th. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and raised their price target for the company from $155.00 to $175.00 in a research report on Tuesday, March 4th. The Goldman Sachs Group lowered Charles River Laboratories International from a "buy" rating to a "neutral" rating and decreased their price objective for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Finally, Evercore ISI upgraded Charles River Laboratories International from an "in-line" rating to an "outperform" rating and set a $170.00 target price on the stock in a report on Thursday, May 8th. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $171.85.

Charles River Laboratories International Stock Performance

NYSE:CRL traded up $1.84 during trading on Wednesday, reaching $150.24. The company's stock had a trading volume of 747,365 shares, compared to its average volume of 1,016,318. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $254.15. The firm has a market cap of $7.38 billion, a price-to-earnings ratio of -231.14, a price-to-earnings-growth ratio of 4.55 and a beta of 1.48. The firm has a 50 day moving average of $133.41 and a 200-day moving average of $154.65. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.16 and a current ratio of 1.43.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, topping analysts' consensus estimates of $2.06 by $0.28. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. The company had revenue of $984.17 million for the quarter, compared to the consensus estimate of $942.34 million. During the same period in the previous year, the firm earned $2.27 EPS. The firm's quarterly revenue was down 2.7% on a year-over-year basis. Research analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).